ParaZero Falls Ahead of Abu Dhabi Confererence
Israel-based ParaZero Technologies Ltd. (NASDAQ: PRZO), shares hesitated Friday. News was handed down that the aerospace company focused on safety systems for commercial unmanned aircrafts and defense Counter UAS systems is set to attend in IDEX UAE 2025, one of the world’s premier defense and security exhibitions.IDEX UAE, held in Abu Dhabi from February 17-21, serves as a strategic platform for defense companies to engage with global military.As drone technology continues to evolve, safety and counter-drone solutions are critical for defense and homeland security operations. At IDEX UAE, ParaZero aims to explore new collaborations and market opportunities with defense officials and industry leaders. The company’s presence to show its growing role in shaping the future of drone safety and security worldwide.ParaZero is a leading developer of autonomous parachute safety systems technologies for commercial and military platforms as well as for urban air mobility (UAM) aircraft. Started in 2014 by a passionate group of aviation professionals and drone industry veterans, ParaZero develops and manufactures smart, autonomous parachute safety systems designed to enable safe flight operations over-populated areas and beyond-visual-line-of-sight (BVLOS) as well as for various military applications including Counter UAS.At the opening on Friday, PRZO shares were in the minus column three cents, or 1.7%, to $1.69.
Recent Posts

Romanian Inflation Ends Tumultuous Year in Politics Close to 10%

UK Boosts Support For Offshore Wind in Bumper Auction

Ireland Is Trying to Get Back on the Data Center Bandwagon

Notice Concerning Change of Representative Executive Officer

Polish Recycler Bets Millions on Europe’s Critical Metals Push

Blistering Metals Rally Sends Silver, Tin and Copper to Records

Wellington Management Appoints Alex Behm to Strengthen Secondaries Capabilities

TCS and AMD Announce Strategic Collaboration to Drive AI Adoption at Scale

New data reinforces Ipsen’s commitment to bringing solutions and addressing care gaps in neurological diseases at TOXINS

TOXINS 2026: Clinical Updates on Galderma’s Leading Neuromodulator Portfolio Further Reinforce Its Leadership in Injectable Aesthetics


